297 related articles for article (PubMed ID: 17560336)
21. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of apoptosis by MAD1 is mediated by repression of the PTEN tumor suppressor gene.
Rottmann S; Speckgens S; Lüscher-Firzlaff J; Lüscher B
FASEB J; 2008 Apr; 22(4):1124-34. PubMed ID: 17998413
[TBL] [Abstract][Full Text] [Related]
23. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
[TBL] [Abstract][Full Text] [Related]
24. Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis.
Martelli AM; Cocco L; Capitani S; Miscia S; Papa S; Manzoli FA
Eur J Histochem; 2007; 51 Suppl 1():125-31. PubMed ID: 17703603
[TBL] [Abstract][Full Text] [Related]
25. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
26. Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells.
Freeley M; Park J; Yang KJ; Wange RL; Volkov Y; Kelleher D; Long A
Cell Signal; 2007 Dec; 19(12):2444-57. PubMed ID: 17826953
[TBL] [Abstract][Full Text] [Related]
27. Loss of phosphatase and tensin homolog (PTEN) induces leptin-mediated leptin gene expression: feed-forward loop operating in the lung.
Pathak RR; Grover A; Malaney P; Quarni W; Pandit A; Allen-Gipson D; Davé V
J Biol Chem; 2013 Oct; 288(41):29821-35. PubMed ID: 23963458
[TBL] [Abstract][Full Text] [Related]
28. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
29. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.
Leenders F; Möpert K; Schmiedeknecht A; Santel A; Czauderna F; Aleku M; Penschuck S; Dames S; Sternberger M; Röhl T; Wellmann A; Arnold W; Giese K; Kaufmann J; Klippel A
EMBO J; 2004 Aug; 23(16):3303-13. PubMed ID: 15282551
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of PTEN and activation of Akt by menadione.
Yoshikawa K; Nigorikawa K; Tsukamoto M; Tamura N; Hazeki K; Hazeki O
Biochim Biophys Acta; 2007 Apr; 1770(4):687-93. PubMed ID: 17276010
[TBL] [Abstract][Full Text] [Related]
31. Phosphatase of regenerating liver 2 (PRL2) deficiency impairs Kit signaling and spermatogenesis.
Dong Y; Zhang L; Bai Y; Zhou HM; Campbell AM; Chen H; Yong W; Zhang W; Zeng Q; Shou W; Zhang ZY
J Biol Chem; 2014 Feb; 289(6):3799-810. PubMed ID: 24371141
[TBL] [Abstract][Full Text] [Related]
32. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
33. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
Mehrian-Shai R; Chen CD; Shi T; Horvath S; Nelson SF; Reichardt JK; Sawyers CL
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5563-8. PubMed ID: 17372210
[TBL] [Abstract][Full Text] [Related]
34. PI3K/PTEN/AKT Genetic Mouse Models of Endometrial Carcinoma.
Joshi A; Ellenson LH
Adv Exp Med Biol; 2017; 943():261-273. PubMed ID: 27910071
[TBL] [Abstract][Full Text] [Related]
35. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Palomero T; Sulis ML; Cortina M; Real PJ; Barnes K; Ciofani M; Caparros E; Buteau J; Brown K; Perkins SL; Bhagat G; Agarwal AM; Basso G; Castillo M; Nagase S; Cordon-Cardo C; Parsons R; Zúñiga-Pflücker JC; Dominguez M; Ferrando AA
Nat Med; 2007 Oct; 13(10):1203-10. PubMed ID: 17873882
[TBL] [Abstract][Full Text] [Related]
36. Role of Tumor Suppressor PTEN and Its Regulation in Malignant Transformation of Endometrium.
Perevalova AM; Kobelev VS; Sisakyan VG; Gulyaeva LF; Pustylnyak VO
Biochemistry (Mosc); 2022 Nov; 87(11):1310-1326. PubMed ID: 36509719
[TBL] [Abstract][Full Text] [Related]
37. Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.
Lin YG; Shen J; Yoo E; Liu R; Yen HY; Mehta A; Rajaei A; Yang W; Mhawech-Fauceglia P; DeMayo FJ; Lydon J; Gill P; Lee AS
Oncogene; 2015 Oct; 34(43):5418-26. PubMed ID: 25684138
[TBL] [Abstract][Full Text] [Related]
38. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Shojaee S; Chan LN; Buchner M; Cazzaniga V; Cosgun KN; Geng H; Qiu YH; von Minden MD; Ernst T; Hochhaus A; Cazzaniga G; Melnick A; Kornblau SM; Graeber TG; Wu H; Jumaa H; Müschen M
Nat Med; 2016 Apr; 22(4):379-87. PubMed ID: 26974310
[TBL] [Abstract][Full Text] [Related]
39. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.
He L; Fan C; Gillis A; Feng X; Sanatani M; Hotte S; Kapoor A; Tang D
Biochim Biophys Acta; 2007 Oct; 1772(10):1134-42. PubMed ID: 17681738
[TBL] [Abstract][Full Text] [Related]
40. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Cully M; You H; Levine AJ; Mak TW
Nat Rev Cancer; 2006 Mar; 6(3):184-92. PubMed ID: 16453012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
